Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Ba133ef361fe135109e6be59735a16e9d> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Ba133ef361fe135109e6be59735a16e9d NCIT_P378 "NCI" @default.
- Ba133ef361fe135109e6be59735a16e9d type Axiom @default.
- Ba133ef361fe135109e6be59735a16e9d annotatedProperty IAO_0000115 @default.
- Ba133ef361fe135109e6be59735a16e9d annotatedSource NCIT_C106432 @default.
- Ba133ef361fe135109e6be59735a16e9d annotatedTarget "A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity." @default.